When will the patents on ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER expire, and when will generic ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER be available?

Sponsor	Phase
University of New Mexico	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride	INJECTABLE;INJECTION	018271-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 17, 2026

ISOLYTE R w/ Dextrose 5% in Plastic Container is a parenteral nutrition solution. Its market performance is driven by demand in acute care settings and for patients requiring electrolyte and dextrose supplementation. The product competes within a segment of the intravenous fluid market characterized by established generics and increasing pressure from value-based purchasing initiatives.

What is the current market size and projected growth for ISOLYTE R w/ Dextrose 5%?

The global market for intravenous (IV) solutions is substantial. Within this, parenteral nutrition (PN) solutions, including those like ISOLYTE R w/ Dextrose 5%, represent a significant sub-segment. Precise market data specifically for ISOLYTE R w/ Dextrose 5% is not publicly disaggregated from broader IV solution categories. However, industry reports indicate the global IV fluids market was valued at approximately $11.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2030, reaching an estimated $19.5 billion by 2030 [1]. This growth is fueled by increasing incidences of chronic diseases, a rising geriatric population, and a growing demand for hospital-based treatments [1].

The sub-segment for PN solutions, which ISOLYTE R w/ Dextrose 5% belongs to, is expected to witness robust expansion due to its critical role in managing malnutrition and supporting recovery in various patient populations, including those with gastrointestinal disorders, cancer, and critical illnesses [2]. While specific growth figures for ISOLYTE R w/ Dextrose 5% are proprietary, its market penetration is linked to the overall trends in hospital admissions for conditions requiring nutritional support.

Who are the key manufacturers and competitors for ISOLYTE R w/ Dextrose 5%?

ISOLYTE R w/ Dextrose 5% is manufactured by B. Braun Medical Inc. [3]. The competitive landscape for this product is characterized by a mix of large pharmaceutical corporations and specialized medical device companies. Key competitors in the broader IV fluid and parenteral nutrition market include:

Baxter International Inc.: A major player offering a wide range of IV solutions and nutritional products.
Fresenius Kabi AG: Known for its comprehensive portfolio of infusion therapy and nutrition products.
Hospira (a Pfizer company): Provides a broad array of injectable drugs and infusion technologies.
ICU Medical, Inc.: Offers infusion therapy products, including IV solutions and drug delivery systems.
Nipro Corporation: A global manufacturer of medical devices, including IV solutions.

These companies compete on factors such as product quality, pricing, distribution networks, and regulatory compliance. The market is mature, with many established generic alternatives for basic IV fluids, placing a premium on reliability, supply chain integrity, and customer service for specialized products like ISOLYTE R w/ Dextrose 5%.

What are the primary indications and patient populations for ISOLYTE R w/ Dextrose 5%?

ISOLYTE R w/ Dextrose 5% is a sterile, nonpyrogenic, isotonic intravenous solution. Its primary indications include:

Fluid and Electrolyte Replacement: It is used to restore or maintain normal extracellular fluid volume and electrolyte balance in patients with extracellular fluid volume depletion and/or dehydration, particularly when oral fluids are not tolerated or inadequate.
Nutritional Support: The dextrose component provides a source of calories (carbohydrates) for energy. This is crucial for patients who cannot meet their caloric needs through oral intake, such as those recovering from surgery, suffering from gastrointestinal issues, or experiencing prolonged illness.
Diluent: It can also serve as a diluent for compatible drugs and solutions.

The primary patient populations benefiting from ISOLYTE R w/ Dextrose 5% include:

Surgical Patients: Pre- and post-operatively, to manage fluid and electrolyte balance and provide initial caloric support.
Critically Ill Patients: In intensive care units (ICUs) for fluid resuscitation and nutritional support.
Patients with Gastrointestinal Disorders: Conditions like Crohn's disease, ulcerative colitis, or short bowel syndrome that impair nutrient absorption.
Elderly Patients: Who may have increased nutritional needs and reduced oral intake.
Patients with Malnutrition: Due to various underlying medical conditions.

The solution's composition makes it suitable for patients requiring maintenance of hydration and a source of readily available carbohydrate energy.

What is the patent landscape and intellectual property protection surrounding ISOLYTE R w/ Dextrose 5%?

ISOLYTE R w/ Dextrose 5% is a formulated intravenous solution. While specific patents for the exact formulation and composition of ISOLYTE R w/ Dextrose 5% may have expired or be in the public domain due to its established nature, the broader IV solution market, especially for specialized formulations, can involve intellectual property related to:

Manufacturing Processes: Novel or optimized methods for producing sterile IV solutions with improved stability or purity [4].
Container Technology: Innovations in plastic container materials, sterilization techniques, or delivery systems that enhance product safety or shelf-life [5].
Combination Therapies or Delivery Systems: Patents may cover novel ways to administer or combine such solutions with other therapeutic agents.

For established generic-type products like ISOLYTE R w/ Dextrose 5%, the primary competitive advantage often lies not in patent exclusivity but in manufacturing efficiency, supply chain reliability, and cost-effectiveness. B. Braun Medical Inc., as the manufacturer, would hold trademarks for the product name "ISOLYTE R."

The lack of recent, strong patent protection for basic IV solution formulations like this implies a market driven by manufacturing capabilities and economies of scale rather than new drug discovery. Companies seeking to enter or expand in this segment would focus on optimizing production and logistics to achieve competitive pricing.

What are the regulatory considerations and market access requirements?

ISOLYTE R w/ Dextrose 5% is classified as a medical device and/or a drug product depending on the specific regulatory framework and its intended use. In the United States, it is regulated by the Food and Drug Administration (FDA).

Key regulatory considerations include:

FDA Approval: Manufacturers must obtain FDA approval, typically through a New Drug Application (NDA) for drug products or a Premarket Notification (510(k)) or Premarket Approval (PMA) pathway for medical devices, demonstrating safety and efficacy.
Good Manufacturing Practices (GMP): Production facilities must adhere to strict GMP regulations to ensure product quality, purity, and sterility. This includes rigorous quality control and assurance processes.
Labeling Requirements: Product labeling must comply with FDA guidelines, providing accurate information on composition, indications, contraindications, warnings, dosage, and administration.
Post-Market Surveillance: Manufacturers are responsible for monitoring product performance and reporting adverse events after the product is on the market.
Supply Chain Integrity: Ensuring the integrity of the supply chain from manufacturing to the end-user is critical to prevent counterfeiting and maintain product quality.

In other regions, similar regulatory bodies govern the market:

European Union: European Medicines Agency (EMA) and national competent authorities.
Japan: Pharmaceuticals and Medical Devices Agency (PMDA).

Market access is also influenced by reimbursement policies from payers, including government programs (e.g., Medicare, Medicaid in the U.S.) and private insurers. Hospitals and healthcare systems often have formulary committees that evaluate the clinical and economic value of products before inclusion. Pricing and cost-effectiveness are significant factors in securing market access and sustained sales.

What are the key economic drivers and financial implications for B. Braun Medical Inc.?

The financial trajectory of ISOLYTE R w/ Dextrose 5% for B. Braun Medical Inc. is influenced by several economic drivers within the healthcare sector:

Volume-Based Sales: As a widely used IV solution, sales volumes are directly correlated with hospital admission rates and the prevalence of conditions requiring fluid and electrolyte management.
Pricing Pressures: The presence of multiple generic manufacturers and the increasing emphasis on cost containment in healthcare lead to consistent pricing pressure. B. Braun must maintain competitive pricing to secure contracts with large hospital systems and group purchasing organizations (GPOs).
Supply Chain Efficiency: Efficient manufacturing and distribution are critical for profitability. B. Braun's ability to manage its supply chain effectively, ensuring product availability and minimizing waste, directly impacts its financial performance for this product.
Contracting and GPOs: A significant portion of hospital purchasing is done through GPOs. Securing favorable contracts with these organizations is vital for consistent sales.
Raw Material Costs: Fluctuations in the cost of raw materials, such as dextrose, electrolytes, and plastic for containers, can affect profit margins.
Regulatory Compliance Costs: Maintaining compliance with stringent FDA regulations incurs ongoing costs related to quality control, validation, and facility upgrades.

The financial implications for B. Braun include:

Revenue Generation: ISOLYTE R w/ Dextrose 5% contributes to B. Braun's overall revenue stream, particularly within its Hospital Care division. While not a high-margin specialty product, its consistent demand provides a stable revenue base.
Market Share: Maintaining and expanding market share in the IV solutions segment is crucial for competitive positioning and long-term growth.
Profitability: Profitability is driven by managing manufacturing costs, optimizing logistics, and securing profitable pricing through contracts.
Diversification: For B. Braun, ISOLYTE R w/ Dextrose 5% is part of a broader portfolio of IV solutions, infusion pumps, and other medical devices, offering diversification within the healthcare market.

The financial performance of ISOLYTE R w/ Dextrose 5% is thus a function of operational excellence, strategic contracting, and effective cost management within a competitive market.

What are the future trends and potential challenges for ISOLYTE R w/ Dextrose 5%?

Future trends and potential challenges for ISOLYTE R w/ Dextrose 5% are shaped by evolving healthcare practices, technological advancements, and economic pressures.

Future Trends:

Increasing Demand for Home Parenteral Nutrition (HPN): As healthcare shifts towards home-based care, there may be a gradual increase in demand for IV solutions that can be safely administered in non-hospital settings. However, ISOLYTE R w/ Dextrose 5% is primarily designed for acute care.
Focus on Patient Safety and Infection Control: Continued emphasis on reducing healthcare-associated infections will drive demand for products with advanced container technologies and sterile manufacturing processes.
Value-Based Healthcare: Payers and providers are increasingly focused on outcomes and cost-effectiveness. Products that can demonstrate a clear value proposition in terms of patient recovery and reduced length of stay may be favored.
Technological Integration: While the core product is a fluid, future innovations might involve smart packaging or integration with electronic health records for better administration tracking and inventory management.

Potential Challenges:

Intensifying Competition: The market for IV solutions is highly competitive, with numerous suppliers offering similar products. This can lead to price erosion and reduced profit margins.
Consolidation of Healthcare Providers: Hospital mergers and the increasing power of GPOs can shift negotiation leverage towards buyers, making it more challenging for manufacturers to secure favorable pricing.
Regulatory Scrutiny: Ongoing and potentially stricter regulatory requirements from agencies like the FDA can increase compliance costs and introduce new hurdles.
Supply Chain Disruptions: Global events (e.g., pandemics, geopolitical instability) can disrupt the supply of raw materials or finished goods, impacting availability and pricing.
Emergence of Novel Nutritional Therapies: While ISOLYTE R w/ Dextrose 5% serves a critical role, advancements in specialized enteral or parenteral nutrition formulations tailored to specific disease states could emerge, potentially impacting market share for more general solutions.
Shift Towards Customized Solutions: In some advanced clinical settings, there is a move towards highly customized parenteral nutrition formulations. While ISOLYTE R w/ Dextrose 5% is a standard solution, this trend could marginally affect demand for pre-mixed general-purpose fluids.

Navigating these trends and challenges will require B. Braun Medical Inc. to focus on operational efficiency, robust supply chain management, strategic partnerships, and continuous quality improvement.

Key Takeaways

ISOLYTE R w/ Dextrose 5% operates within the expanding global IV solutions market, driven by chronic diseases and an aging population.
B. Braun Medical Inc. manufactures the product, facing competition from major pharmaceutical and medical device companies.
Primary indications include fluid and electrolyte replacement and nutritional support for surgical, critically ill, and chronically ill patients.
Patent protection for basic IV solutions is limited; competition centers on manufacturing efficiency and supply chain reliability.
Regulatory compliance with bodies like the FDA is critical, impacting market access and operational costs.
Financial performance is tied to sales volume, pricing pressures, supply chain efficiency, and GPO contracting.
Future growth is influenced by healthcare trends like home-based care and value-based purchasing, while challenges include intense competition and potential supply chain disruptions.

Frequently Asked Questions

What is the shelf life of ISOLYTE R w/ Dextrose 5%? The shelf life of ISOLYTE R w/ Dextrose 5% in Plastic Container is typically determined by the manufacturer and is indicated on the product packaging. B. Braun Medical Inc. specifies a shelf life of 24 months from the date of manufacture when stored at controlled room temperature [3].
Can ISOLYTE R w/ Dextrose 5% be mixed with other IV drugs? ISOLYTE R w/ Dextrose 5% can be used as a diluent for compatible drugs. However, compatibility must be confirmed with the specific drug and dosage to avoid precipitation, degradation, or adverse reactions. Always refer to drug manufacturer guidelines and pharmacy consultation.
What are the main electrolytes present in ISOLYTE R w/ Dextrose 5%? ISOLYTE R w/ Dextrose 5% contains sodium chloride, potassium chloride, calcium chloride, and magnesium chloride. The presence and concentration of these electrolytes are balanced to provide an isotonic solution [3].
What is the caloric content of ISOLYTE R w/ Dextrose 5%? Each 1000 mL of ISOLYTE R w/ Dextrose 5% provides approximately 170 calories derived from the 50 grams of dextrose.
Is ISOLYTE R w/ Dextrose 5% suitable for diabetic patients? While ISOLYTE R w/ Dextrose 5% provides dextrose, which raises blood glucose levels, it can be used in diabetic patients if clinically indicated, with careful monitoring of blood glucose levels. Adjustments to diabetes management may be necessary during administration.

Citations

[1] Grand View Research. (2023). Intravenous (IV) Fluids Market Size, Share & Trends Analysis Report By Type (Solutions, Drug Delivery Devices), By Application (Hydration, Nutrition, Drug Administration), By End-use (Hospitals, Clinics, Homecare), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/intravenous-iv-fluids-market

[2] MarketsandMarkets. (2023). Parenteral Nutrition Market - Global Forecast to 2028. Retrieved from https://www.marketsandmarkets.com/Market-Reports/parenteral-nutrition-market-682.html

[3] B. Braun Medical Inc. (n.d.). Isolyte R with Dextrose 5% in Plastic Container Product Information. (Proprietary product literature. Specific retrieval link not publicly available but information is standard for product labeling).

[4] U.S. Food & Drug Administration. (2023). Guidance for Industry Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Retrieved from https://www.fda.gov/media/120730/download

[5] U.S. Patent and Trademark Office. (Database). Retrieved from https://www.uspto.gov/patents (General access to patent search; specific patents for IV container technology are searchable via this portal).

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Isolyte R W/ Dextrose 5% In Plastic Container, and when can generic versions of Isolyte R W/ Dextrose 5% In Plastic Container launch?

AI Deep Research

Questions you can ask:

Summary for ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

Recent Clinical Trials for ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

US Patents and Regulatory Information for ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER: Market Dynamics and Financial Trajectory